{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:47:03Z","timestamp":1761630423000},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm World Sci"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1007\/s11096-006-9022-x","type":"journal-article","created":{"date-parts":[[2006,9,26]],"date-time":"2006-09-26T12:20:39Z","timestamp":1159273239000},"page":"123-125","source":"Crossref","is-referenced-by-count":11,"title":["Bacterial meningitis associated with infliximab"],"prefix":"10.1007","volume":"28","author":[{"given":"Raymond","family":"Farah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Lisitsin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshe","family":"Shay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,9,27]]},"reference":[{"issue":"2","key":"9022_CR1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00063030-200418020-00005","volume":"18","author":"LM Bang","year":"2004","unstructured":"Bang LM, Keating GM. Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs 2004;18(2):121\u201339","journal-title":"BioDrugs"},{"key":"9022_CR2","first-page":"31","volume":"74","author":"PP Tak","year":"2005","unstructured":"Tak PP. Effects of infliximab treatment on rheumatoid synovial tissue. J Rheumatol Suppl 2005 Mar;74:31\u20134","journal-title":"J Rheumatol Suppl"},{"issue":"2","key":"9022_CR3","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D Heijde Van\u00a0der","year":"2005","unstructured":"Van\u00a0der\u00a0Heijde D, Dijkmans B, et\u00a0al. Ankylosing spondylitis study for the evaluation of recombinant infliximab therapy study group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005 Feb;52(2):582\u201391","journal-title":"Arthritis Rheum"},{"issue":"1","key":"9022_CR4","first-page":"10","volume":"5","author":"WJ Sandborn","year":"2005","unstructured":"Sandborn WJ. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev Gastroenterol Disord 2005 Winter;5(1):10\u20138","journal-title":"Rev Gastroenterol Disord"},{"issue":"9\u201310","key":"9022_CR5","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/BF03040906","volume":"116","author":"J Kleinert","year":"2004","unstructured":"Kleinert J, Lorenz M, Kostler W, et\u00a0al. Refractory Wegener\u2019s granulomatosis responds to tumor necrosis factor blockade. Wien Klin Wochenschr 2004 May 31;116(9\u201310):334\u20138","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"9022_CR6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01.bor.0000200369.24793.f5","volume":"18","author":"B Hellmich","year":"2006","unstructured":"Hellmich B, Lamprecht P, Gross WL. Advances in the therapy of Wegener\u2019s granulomatosis. Curr Opin Rheumatol 2006 Jan;18(1):25\u201332","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"9022_CR7","first-page":"756","volume":"22","author":"Y Allanore","year":"2004","unstructured":"Allanore Y, Sellam J, Batteux F, et\u00a0al. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin Exp Rheumatol 2004 Nov\u2013Dec;22(6):756\u20138","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"9022_CR8","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/01.SMJ.0000155499.21189.75","volume":"98","author":"N Hegde","year":"2005","unstructured":"Hegde N, Gayomali C, Rich MW. Infliximab-induced headache and infliximab-induced meningitis: two ends of the same spectrum? South Med J 2005 May;98(5):564\u20136","journal-title":"South Med J"},{"issue":"1","key":"9022_CR9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1345\/aph.1D151","volume":"38","author":"VL Bowie","year":"2004","unstructured":"Bowie VL, Snella KA, Gopalachar AS, Bharadwaj P. Listeria meningitis associated with infliximab. Ann Pharmacother 2004 Jan;38(1):58\u201361","journal-title":"Ann Pharmacother"},{"issue":"9313","key":"9022_CR10","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(02)08241-7","volume":"359","author":"AS Kashyap","year":"2002","unstructured":"Kashyap AS, Kashyap S. Infliximab-induced aseptic meningitis. Lancet 2002 Apr 6;359(9313):1252","journal-title":"Lancet"},{"issue":"5","key":"9022_CR11","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s10067-005-1085-x","volume":"24","author":"JA Batsis","year":"2005","unstructured":"Batsis JA, Phy MP. West Nile virus meningitis in a chronic immunosuppressed patient with rheumatoid arthritis. Clin Rheumatol 2005 Sep;24(5):548\u201350. Epub 2005 Apr 23","journal-title":"Clin Rheumatol"},{"issue":"9295","key":"9022_CR12","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/S0140-6736(01)06810-6","volume":"358","author":"H Marotte","year":"2001","unstructured":"Marotte H, Charrin JE, Miossec P. Infliximab-induced aseptic meningitis. Lancet 2001 Nov 24;358(9295):1784","journal-title":"Lancet"},{"issue":"6","key":"9022_CR13","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.162.6.2163","volume":"162","author":"JM Dayer","year":"1985","unstructured":"Dayer JM, Beutler B, Cerami A. Cachectin\/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985 Dec 1;162(6):2163\u20138","journal-title":"J Exp Med"},{"issue":"6079","key":"9022_CR14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/322547a0","volume":"322","author":"J Saklatvala","year":"1986","unstructured":"Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986 Aug 7\u201313;322(6079):547\u20139","journal-title":"Nature"},{"issue":"15","key":"9022_CR15","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, et\u00a0al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001 Oct 11;345(15):1098\u2013104","journal-title":"N Engl J Med"},{"issue":"2","key":"9022_CR16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et\u00a0al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981 Aug;30(2):239\u201345","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 2","key":"9022_CR17","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1136\/annrheumdis-2013-203348","volume":"63","author":"DE Furst","year":"2004","unstructured":"Furst DE, Breedveld FC, Kalden JR, et\u00a0al. Updated consensus statement on biological agents, specifically tumour necrosis factor-\u03b1 (TNF-\u03b1) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 2004 Nov;63(Suppl. 2):ii2\u2013ii12","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"9022_CR18","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1136\/ard.2004.024737","volume":"63","author":"KL Hyrich","year":"2004","unstructured":"Hyrich KL, Silman AJ, Watson KD, Symmons DP. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 2004 Dec;63(12):1538\u201343","journal-title":"Ann Rheum Dis"}],"container-title":["Pharmacy World and Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-006-9022-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-006-9022-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-006-9022-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T05:51:29Z","timestamp":1559368289000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-006-9022-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["9022"],"URL":"https:\/\/doi.org\/10.1007\/s11096-006-9022-x","relation":{},"ISSN":["0928-1231","1573-739X"],"issn-type":[{"value":"0928-1231","type":"print"},{"value":"1573-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}